Why is Elekta stock sliding today?

Elekta shares fell 3.9% to 49.6 SEK, hitting an intraday low of 49.54 SEK, after its Capital Markets Day outlined mid-term targets that investors appear to view as insufficiently ambitious. The company guided to mid-single-digit constant-currency sales growth for FY 2025/26-FY 2028/29, an adjusted EBIT margin of 14%-16% in FY 2028/29, and free cash flow of about 10% of sales, but skepticism remains elevated after the weak May 28 Q4 results. UBS rates the stock sell and Morgan Stanley underweight, while short interest is rising and the shares trade about 26% below the 52-week high of 66.7 SEK.

Analysis

Elekta’s guidance reset is less about the absolute numbers than the implied sequencing: management is asking the market to underwrite a multiyear turnaround while near-term order visibility remains weak. In that setup, the stock can stay broken for longer than fundamentals warrant because short interest and analyst positioning create a reflexive feedback loop — weak tape begets more skepticism, which raises the hurdle for any future beat.

The second-order issue is competitive rather than purely financial. If the company must prioritize U.S. penetration and China expansion at the same time, it risks spending into markets where procurement cycles are long and incumbents have entrenched service relationships, so incremental share gains may require margin concessions before they show up in revenue. That dynamic tends to favor larger, better-capitalized medtech peers and system integrators with broader installed bases, while smaller adjacent vendors can benefit if Elekta’s customers delay replacement decisions.

The key catalyst path is not the CMD itself but the next 1-2 reporting windows: any improvement in order intake, backlog quality, or cash conversion would matter more than long-dated margin targets. If those metrics do not turn within the next two quarters, the market will likely re-rate this as a valuation trap rather than a turnaround, especially in a risk-off tape where long-duration stories are being de-rated.

Contrarianly, the selloff may already be discounting a fairly low probability of execution, which creates asymmetry if management can simply stabilize expectations rather than outperform them. The market is pricing skepticism about credibility; a modest operational inflection could force shorts to cover quickly because the float is crowded, but without that inflection the stock can drift lower on liquidity and sentiment alone.

Key Decisions for Investors

• Short EKTAB on any post-CMD bounce into the 51-53 SEK area over the next 1-2 sessions; target 45-46 SEK on continued order-intake skepticism, with stop above 54.5 SEK if the market starts rewarding the guidance reset.
• For a cleaner relative-value expression, pair long a higher-quality medtech leader vs short EKTAB over the next 1-3 months; the trade works if investors continue to favor companies with clearer cash conversion and less execution risk.
• Buy short-dated downside optionality on EKTAB if implied vol remains below realized post-CMD volatility; 1-2 month puts offer convexity if the market concludes the targets are aspirational rather than credible.
• Avoid buying the stock purely on valuation until the next two quarterly order prints confirm stabilization; the risk/reward remains skewed against catching a falling knife while short interest is still building.